Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Decitabine + Rasdegafusp alfa|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Decitabine||Dacogen||5-aza-2-deoxycytidine||DNMT inhibitor (Pan) 5||Dacogen (decitabine) is cytidine analog that incorporates into DNA and forms covalent bonds with DNA methyltransferases (DNMTs), resulting in decreased DNMT activity and hypomethylation, and potentially leading to reduced tumor growth (PMID: 28159832, PMID: 25130173). Dacogen (decitabine) is FDA approved for use in patients with myelodysplastic syndromes (FDA.gov).|
|Rasdegafusp alfa||CDX-1401|DEC-205/NY-ESO-1 fusion protein vaccine||Rasdegafusp alfa (CDX-1401) is a DEC-205/NY-ESO-1 fusion protein vaccine that consists of a monoclonal antibody directed against the dendritic cell receptor DEC-205 linked to the tumor-associated antigen DEC-205/NY-ESO-1 fusion protein, which may boost the immune system to attack cancer cells expressing DEC-205/NY-ESO-1 fusion protein (PMID: 24739759).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT01834248||Phase I||Decitabine + Rasdegafusp alfa||DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia||Completed||USA||0|